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ABSTRACT
Objective Endoscopic full- thickness resection (EFTR) 
has shown efficacy and safety in the colorectum. The 
aim of this analysis was to investigate whether EFTR is 
cost- effective in comparison with surgical and endoscopic 
treatment alternatives.
Design Real data from the study cohort of the 
prospective, single- arm WALL RESECT study were used. 
A simulated comparison arm was created based on a 
survey that included suggested treatment alternatives 
to EFTR of the respective lesions. Treatment costs and 
reimbursement were calculated in euro according to 
the coding rules of 2017 and 2019 (EFTR). R0 resection 
rate was used as a measure of effectiveness. To assess 
cost- effectiveness, the average cost- effectiveness ratio 
(ACER) and the incremental cost- effectiveness ratio (ICER) 
were determined. Calculations were made both from the 
perspective of the care provider as well as of the payer.
Results The cost per case was €2852.20 for the EFTR 
group, €1712 for the standard endoscopic resection 
(SER) group, €8895 for the surgical resection group and 
€5828 for the pooled alternative treatment to EFTR. From 
the perspective of the care provider, the ACER (mean cost 
per R0 resection) was €3708.98 for EFTR, €3115.10 for 
SER, €8924.05 for surgical treatment and €7169.30 for 
all pooled and weighted alternatives to EFTR. The ICER 
(additional cost per R0 resection compared with EFTR) 
was €5196.47 for SER, €26 533.13 for surgical resection 
and €67 768.62 for the pooled rate of alternatives. Results 
from the perspective of the payer were similar.
Conclusion EFTR is cost- effective in comparison with 
surgical and endoscopic treatment alternatives in the 
colorectum.
INTRODUCTION
Colorectal cancer is the third most common 
type of cancer and the second most common 
cause of cancer- related deaths worldwide.1 
Screening programmes for early detection 
of premalignant and malignant lesions led 
to a significant reduction in cancer- related 
mortality.2 With more intense screening more 
lesions are detected, which automatically 
creates the need for removal. Standard endo-
scopic resections (SER) such as endoscopic 
mucosal resection (EMR) and endoscopic 
submucosal dissection (ESD) are well estab-
lished and sufficient for the vast majority of 
lesions. However, SER of non- lifting lesions 
and lesions located at difficult anatomical 
Summary box
What is already known about this subject?
 ► Endoscopic full- thickness resection (EFTR) has 
shown clinical efficacy and safety in difficult- to- 
treat lesions in the colorectum.
 ► The cost of the full- thickness resection device is 
higher than the cost of standard endoscopic resec-
tion (SER) devices but lower than surgical devices.
 ► Cost- effectiveness analyses on treatment with EFTR 
compared with treatment alternatives do not exist.
What are the new findings?
 ► EFTR leads to an almost 60% reduction in cost 
per R0 resection (average cost- effectiveness ratio) 
compared with surgery.
 ► To achieve an additional R0 resection by surgical 
treatment compared with EFTR (incremental cost- 
effectiveness ratio), an additional cost of €27 000 
is necessary.
 ► These findings are consistent both from the per-
spective of the care provider as well as the payer.
How might it impact on clinical practice in the 
foreseeable future?
 ► In terms of cost- effectiveness, EFTR should be 
considered first before patients with difficult- to- 
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locations (eg, appendiceal orifice) is associated with 
increased complication rates or incomplete resection.3–5 
These types of lesions are therefore often referred to 
surgery, which is associated with significant morbidity 
and mortality and higher costs.6 Given the high number 
of polypectomies performed worldwide, this is not only 
an issue of morbidity and mortality, but also a huge 
economic challenge.
The efficacy and safety of endoscopic full- thickness 
resection (EFTR) of non- lifting and other difficult- to- 
treat lesions have been demonstrated in multiple retro-
spective studies and in one prospective study.7 8 The cost 
of the device is markedly higher than SER devices, but 
lower than surgical treatment. The aim of the present 
analysis was to evaluate whether EFTR is cost- effective in 
comparison with SER as well as surgical treatment.
METHODS
Study population
To calculate the cost of EFTR, we analysed the study 
cohort of the WALL RESECT trial (NCT02362126). 
In this single- arm, multicentre, prospective study, 181 
patients with ‘difficult- to- treat’ adenomas (eg, non- lifting 
and/or challenging anatomical location), early adeno-
carcinomas and subepithelial tumours in the colorectum 
were treated with EFTR. The primary endpoints of the 
study, en bloc and R0 resection rate, were achieved in 
89.5% and 76.9%, respectively.7 Written, informed 
consent was obtained from each patient included in the 
study.
Simulation second study arm based on a survey of 
endoscopists
With the WALL RESECT study being single- armed, a 
second study arm was created based on treatment simula-
tion. In order to compare different treatment modalities, 
a case report form (CRF) was created and sent to each 
participating centre of the WALL RESECT trial. Endos-
copists at the respective location reviewed the endoscopic 
images and their case- relevant data and decided which 
treatment modality they would have chosen if EFTR were 
not available. Treatment alternatives included SER, such 
as EMR, thermal methods and ESD, as well as surgical 
resection. The CRF was filled out in a pseudonymised 
fashion.
Informed consent had already been obtained within 
the WALL RESECT study.
Determination of case costs and reimbursement
A certified online IT tool, the Diagnosis Related Group 
(DRG) Web Grouper, was used to determine the reim-
bursement rate for each patient (http:// drg. uni- 
muenster. de/ index. php). Therefore, the code of the 
International Classification of Diseases (ICD-10) and 
the specific code for the procedure performed (Oper-
ationen- und Prozedurenschlüssel (OPS) code) in each 
patient in both groups were put into the Web Grouper. 
Together with the predefined mean length of hospital 
stay (‘mittlere Grenzverweildauer’) the DRG, which 
accounts for reimbursement, was calculated.
In the comparison arm, the DRG codes of 2017 were 
used because this was the year the WALL RESECT study 
was performed. For the EFTR arm, the DRG codes of 2019 
were used, as reimbursement for EFTR was increased 
that year.
To calculate the cost per case, another certified online 
IT tool (G- DRG- Report Browser) was used (https://www. 
g- drg. de/ G- DRG- System_ 2019/ Abschlussbericht_ zur_ 
Weiterentwicklung_ des_ G- DRG- Systems_ und_ Report_ 
Browser). This was done by filling in the respective DRG, 
ICD-10 and OPS code into the browser. The data of the 
G- DRG- Report Browser 2019 derive from the data that 
were sent in to InEK (authority managing the German 
DRG system) by certified hospitals (‘Kalkulationshäuser’) 
in 2017. Grouping was performed following the rules 
of G- DRG 2017/2019 version. The main and secondary 
diagnoses are shown according to ICD-10- german modifi-
cation (GM) 2017 version and the procedures according 
to OPS 2017 version (‘G- DRG- Report Browser 2019, InEK 
GmbH’).
As reimbursement for the EFTR group was taken from 
2019, the cost per patient case would ideally also have 
been calculated from 2019. Unfortunately, these data 
will be first published by InEK in 2021. To overcome this 
problem, costs for EFTR cases from the University of 
Freiburg between 2017 and 2019, which were reported to 
InEK, were used for the analysis.
With the cost of each patient case, the mean cost 
for each treatment modality (EMR, ESD, laparoscopic 
surgery, transanal endoscopic microsurgery (TEM), 
EFTR) could be calculated. In the next step, the mean 
cost for each treatment path (SER, surgical treatment 
and casemix alternative) was determined. This was done 
in the following fashion: for SER, the mean costs of EMR 
and ESD were used. For calculation of the surgical treat-
ment, laparoscopic surgery and TEM were taken together. 
The mean costs of endoscopic and surgical treatments 
were subsumed as the casemix alternative.
Determination of effectiveness
The R0 resection rate was defined as the efficacy param-
eter to determine cost- effectiveness. The R0 rate of 
EFTR in the WALL RESECT trial was 76.9% (0.769). To 
determine the efficacy of the therapeutic alternatives 
to EFTR, a selective literature review was performed in 
PubMed and Cochrane databases identifying the largest 
studies comparing resection techniques and R0 rates. 
The respective rates regarding SER found in the litera-
ture were 42.3% (0.423) for EMR and 74.6% (0.746) for 
ESD.9 10 For the surgical oncological resection treatment 
as the gold standard, a 100% (0.100) R0 resection rate 
was assumed. For the TEM, a rate of 88.5% (0.885) had 
been reported.10
In order to compare all SER methods (EMR+ESD), all 
surgical resection methods (laparoscopic surgery+TEM) 
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‘casemix alternative’) with the EFTR procedure, a 
combined effectiveness of each treatment group was 
calculated. This was done by multiplication of the number 
of patients in each modality (eg, 45 EMR cases) with the 
respective R0 resection rate (0.423) as the first step. In 
the second step, this result would be summed up to the 
result of the other modalities (eg, ESD+EMR result for 
the SER methods) and divided by the number of patients 
in this group of resection method (eg, 74 patients in the 
SER group). Using this approach, the ‘overall’ efficacy in 
the SER group was calculated as 54.9% (0.549). Overall 
efficacy of surgical treatment and casemix alternative 
was performed in the same manner and was calculated 
as 99.7% (0.997) and 81.2% (0.812), respectively. The 
respective R0 rates are shown in table 1.
Calculation of cost-effectiveness
For assessment of cost- effectiveness, the average cost- 
effectiveness ratio (ACER) and the incremental cost- 
effectiveness ratio (ICER) were calculated. ACER 
expresses the mean costs for the investigated outcome.11 
In our study, ACER describes the mean costs per successful 
R0 resection in the different treatment modalities.





ICER expresses the additional costs of a treatment alter-
native for improvement in the investigated outcome.12 In 
our study, these are the incremental costs for the alter-
native treatment to EFTR required to achieve an R0 
resection.
ICER is calculated with the following computational 
formula:
 ICER =
mean costs intervention−mean costs control
effect intervention− effect control  
The mean costs were the total costs of the respective 
treatment modality divided by the number of patients 
in each group. For the calculation of cost- effectiveness, 
the SER methods (EMR and ESD) as well as the surgical 
resection methods (laparoscopic resection and TEM) 
were taken together. Furthermore, cost- effectiveness was 
calculated for the casemix alternative to compare EFTR 
with all alternatives.
RESULTS
Comparative study arm/endoscopist survey
From 181 patients of the study cohort, 180 responses were 
included for further analysis. In one patient, the investi-
gator recommended solely ‘thermal ablation’ as alterna-
tive treatment of choice; thus, the primary endpoint R0 
resection could not be evaluated. From the remaining 
180 patients, the endoscopists recommended surgical 
treatment in 59% (106 of 180) of cases. Thereof, 97% 
(103 of 106) were laparoscopic resections and 3% (3 of 
106) TEM. In 41% (74 of 180) of cases, an endoscopic 
resection was proposed. Thereof, 61% (45 of 74) were 
EMR and 39% (29 of 74) were ESD.
Costs from the perspective of the care provider
Costs per case were derived from the DRG- Report 
Browser 2019 which represent costs of the respective 
treatment alternative for the year 2017. The costs for the 
EFTR treatment were derived from University Hospital 
Freiburg and represent the mean costs from years 2017 
to mid-2019. The mean cost for EFTR was €2852.20. 
The cost per surgical treatment (laparoscopic surgery 
and TEM) was €8895 and for SER €1712. All alterna-
tive treatment strategies ‘casemix alternative’ (OP lapar-
scopic surgery, TEM, ESD, and EMR) were calculated as 
€5828 per case. The results are shown in figure 1.
Costs from the perspective of the third-party
According to the German DRG System, reimbursement 
for EFTR is €3069. For surgical treatment €9619 was 
calculated. The cost per case for SER is €1646. The cost 
for the casemix alternative is €8437. The results are 
shown in figure 1.
Cost-effectiveness analysis: care provider viewpoint
Average cost-effectiveness ratio
The mean cost per R0 resection is €3708.98 in the 
EFTR group and €8924.05 in the surgical group. In 
the SER group, the cost per R0 resection is €3115.10. 
In the casemix alternative group, including all treatment 
Table 1 Alternative treatment strategies to EFTR with 
their respective efficacy based on literature review and 
calculation




TEM 3 88.5 (Arezzo et al, 
2014)10
EMR 45 42.3 (Fujiya et al, 
2015)9





SER (EMR+ESD) 74 54.9 (calculated)
Casemix alternative 180 81.2 (calculated)
The combined effectiveness of surgical treatment, SER and 
casemix alternative was calculated by multiplication of the number 
of patients in each modality (eg, 45 EMR cases for SER) with the 
respective R0 resection rate (0.423) as the first step. In the second 
step, this result would be summed up to the result of the other 
modalities (eg, ESD+EMR result for the SER methods) and divided 
by the number of patients in this group of resection method (eg, 74 
patients in the SER group). Overall efficacy of surgical treatment 
and casemix alternative was performed in the same manner.
EFTR, endoscopic full- thickness resection; EMR, endoscopic 
mucosal resection; ESD, endoscopic submucosal dissection; 


















astroenterol: first published as 10.1136/bm





4 Kuellmer A, et al. BMJ Open Gastro 2020;7:e000449. doi:10.1136/bmjgast-2020-000449
Open access 
alternatives except EFTR, the mean cost per R0 resection 
is €7169.30. The results are shown in figure 2.
Incremental cost-effectiveness ratio
In comparison with EFTR, the incremental cost for an 
additional R0 resection is €5196.47, if SER is performed. 
The cost for the surgical approach is €26 533.13 and for 
the casemix alternative €67 768.62. The results are shown 
in figure 3.
Cost-effectiveness analysis: health insurance 
reimbursement viewpoint
Average cost-effectiveness ratio
From the perspective of the health insurance, the cost 
per R0 resection is €3990.90 in the EFTR group. In the 
SER group, the cost is €2995.01 and in the surgical treat-
ment group €9650.41. In the casemix alternative, the 
cost per R0 resection is €10 378.75. The results are shown 
in figure 2.
Incremental cost-effectiveness ratio
The ICER of SER in comparison with EFTR is €6485.31. 
The surgical approach costs an additional €28 760.20. 
For the casemix alternative €122 246.96 is necessary 
for an additional R0 resection. The results are shown in 
figure 3.
DISCUSSION
With technical endoscopic progress, patient care has 
constantly improved over the years; however, as with any 
technical innovation, this is associated with higher costs. 
Therefore, the efficacy of new methods and devices needs 
to be evaluated in relation to their costs.13 To our knowl-
edge, this is the first cost- effectiveness analysis (CEA) for 
EFTR. Our results demonstrate that EFTR for difficult- 
to- treat lesions in the colorectum is cost- effective in 
comparison with SER as well as surgical therapy. Further-
more, the results are consistent when analysed from the 
perspective of the care provider as well as of the payer.
Figure 1 Case costs (€) for the different treatment 
modalities are shown. Costs from the perspective of the 
third- party payer (reimbursement) are shown in black, 
while actual case costs from the perspective of the care 
provider are shown in grey. Surgery: mean costs for TEM 
and laparoscopic surgical oncological resection. SER: mean 
costs for ESD and EMR. Casemix: mean costs for ESD, 
EMR, TEM and laparoscopic surgery. EFTR, endoscopic 
full- thickness resection; EMR, endoscopic mucosal 
resection; ESD, endoscopic submucosal dissection; SER, 
standard endoscopic resection; TEM, transanal endoscopic 
microsurgery.
Figure 2 Average cost- effectiveness ratio (€) for the 
different treatment modalities is shown. Costs from the 
perspective of the third- party payer (reimbursement) are 
shown in black, while actual case costs from the perspective 
of the care provider are shown in grey. Surgery: mean costs 
for TEM and laparoscopic surgical oncological resection. 
SER: mean costs for ESD and EMR. Casemix: mean costs 
for ESD, EMR, TEM and laparoscopic surgery. EFTR, 
endoscopic full- thickness resection; EMR, endoscopic 
mucosal resection; ESD, endoscopic submucosal dissection; 
SER, standard endoscopic resection; TEM, transanal 
endoscopic microsurgery.
Figure 3 Incremental cost- effectiveness ratio for the 
different treatment modalities compared with EFTR is 
shown. Costs from the perspective of the third- party payer 
(reimbursement) are shown in black, while actual case costs 
from the perspective of the care provider are shown in grey. 
Surgery: mean costs for TEM and laparoscopic surgical 
oncological resection. SER: mean costs for ESD and EMR. 
Casemix: mean costs for ESD, EMR, TEM and laparoscopic 
surgery. EFTR, endoscopic full- thickness resection; 
EMR, endoscopic mucosal resection; ESD, endoscopic 
submucosal dissection; SER, standard endoscopic resection; 
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For our analysis, a simulated control arm was created. 
This was necessary as to date no randomised controlled 
trial (RCT) investigating EFTR versus alternative treat-
ments has been published. In our survey, endoscopists 
proposed surgical treatment as the likely alternative to 
EFTR in the majority (59%) of cases as opposed to SER 
via EMR or ESD (41%). All lesions within the WALL 
RESECT trial were ‘difficult- to- resect’ lesions (eg, non- 
lifting adenomas) exhibiting a high risk of perforation 
or incomplete resection when treated with SER. There-
fore, it may be surprising that SER was suggested in 
41% of cases. However, the suggestions were made by 
expert endoscopists who might have decided towards an 
advanced endoscopic procedure more generously.
Regarding the costs for each treatment modality, it was 
not surprising that the cost of EFTR is 40% above SER 
(€2852 vs €1712). This is due to the cost of the device 
(in Germany €849 plus value- added tax). However, the 
cost of EFTR was roughly one- third of the cost of surgery 
(€2852 vs €8895). This reflects the minimally invasive 
nature of EFTR compared with laparoscopic or open 
surgical operations.
While costs for endoscopic resection and surgical 
therapy were taken from official and certified tools (Web 
Grouper and DRG- Report Browser), the factual costs of 
the EFTR procedure for the year 2019 that are deter-
mined in a representative cross- section of hospitals have 
not been published yet by InEK, the administrator of the 
DRG system. Reimbursement of the procedure changed 
in 2019; thus, these data should have been used for calcu-
lation. To overcome this problem, the mean case costs 
for EFTR per case in our home institution (University 
Hospital of Freiburg, Germany) in the time between 2017 
and 2019 were used as a surrogate. In 2019, an economic 
analysis of the cost of EFTR in Germany (presented at 
the annual conference of the German Society for Diges-
tive Diseases 2019) obtained from different endoscopic 
centres reported €3058 per case. As this is only 7% above 
our number and therefore in the same range, our calcu-
lated €2852 seems to be a realistic number.14
In our analysis, we chose the R0 rate as a means to 
detemine effectiveness, as this is the most objective 
parameter to assess curative resection and treatment 
success. Furthermore, the R0 rate can be compared with 
the treatment alternatives of EFTR, as high- quality meta- 
analyses and therapeutic success rates exist for those 
procedures.10 15 The R0 rate for surgical colonic resection 
was assumed to be 100%. However, the patient cohorts 
of these studies are not equal: the WALL RESECT study 
included only ‘difficult- to- resect’ lesions (mainly non- 
lifting), while the studies mentioned above included 
primarily treatment- naive lesions. Larger studies on SER 
on non- lifting lesions do not exist. Hence, it is reasonable 
to assume that in these indications real R0 rates of SER 
would be lower and therefore cost- effectiveness would be 
even worse.
For measuring cost- effectiveness, ACER and ICER 
were determined. The analysis was performed both 
from the perspective of the care provider (hospital) as 
well as the reimbursement authority (health insurance). 
ACER expresses the mean cost per R0 resection. For both 
investigated perspectives, our results reveal that costs are 
much lower for EFTR compared with the surgical alterna-
tive. Although the effectiveness of the surgical approach 
in terms of radicality can be considered to be higher, 
EFTR is cost- effective. An R0 resection by EFTR leads 
to nearly 60% reduction in costs for the care provider 
(€3708.98/€8924.05=0.42) and for the health insurance 
(€3990.90/€9650.41=0.41). Compared with SER, EFTR 
leads to marginally higher costs per R0 resection. As 
explained above, comparing EFTR with SER has limita-
tions as the investigated ‘difficult’ lesions in the WALL 
RESECT study are not well studied for EMR and ESD. 
However, in comparison with all treatment alternatives 
(‘casemix alternative’), we calculated 49% and 64% 
reduction in costs (similar to the surgical alternatives) 
(figure 2).
ICER expresses the additional costs for an additional 
increase in the designated outcome. In our analysis, it 
expresses the additional costs that are necessary for an 
additional R0 resection. As shown in figure 3, all alter-
natives to EFTR result in additional costs. While SER 
results in a modest increase (€5196.47 and €6485.31), 
additional €26 533.13 and €28 760.20 per R0 resection 
are required in the surgical group. In the ‘casemix alter-
native’ group, additional costs were €67 768.62 and €122 
246.96, respectively.
An absolute threshold at which an ICER is thought 
to be cost- effective does not exist.16 In the literature 
the willingness- to- pay threshold ranges from 0 to 
$50 000–$100 000 and is highly subjective to the investi-
gated outcome and the healthcare system for which the 
CEA is made.17–21 For our analysis, we assume that a more 
invasive treatment that produces at least €25 000 more 
costs for an additional R0 resection cannot be regarded 
as being cost- effective.
For our analysis, we did not include costs of follow- up 
endoscopies or further treatment arising from recur-
rency or from adverse events. This was done due to the 
following reasons: first, reliable recurrence rates and 
long- term follow- up after EFTR do not exist. Follow- up 
in the WALL RESECT trial was only 12 weeks. Second, 
the lesions of our patient cohort were heterogeneous, 
including adenomas, carcinomas and neuroendocrine 
tumours, with different biological features and recurrent 
rates. Third, treatment of recurrent lesions is not stan-
dardised and ranges from re- EFTR to snare polypectomy, 
to removal with a biopsy forceps, leading to highly vari-
able costs. Fourth, management of severe complications 
and consecutive morbidity differs in every patient and 
depends on severity of complication, patients’ comor-
bidities and local expertise. We do not have reliable data 
on costs for such treatment and a hypothetical model 
would have been highly speculative. Moreover, in the 
WALL RESECT trial, 2.2% of patients required consec-
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higher but still grossly comparable with the complication 
rates of EMR and ESD. On the other hand, complica-
tions after surgical resection (eg, anastomotic leakage) 
are much more frequent (up to 15%–30%) and usually 
lead to higher morbidity. Hence, even if costs related to 
complications were added, ICER is still likely to favour 
EFTR compared with the group of treatment alternatives.
It is difficult to compare our results with other CEAs as 
this is the first one for this indication. The only previous 
CEA on SER compared EMR and ESD in laterally 
spreading lesions irrespective of location or lifting sign. In 
most analyses, as in the study by Bahin and colleagues,19 
a decision tree model was created to compare different 
outcome scenarios. After each treatment path was filled 
with probabilities of occurrence, costs per predefined 
outcome were calculated. A potential bias of this 
approach is that the data for the probabilities of occur-
rence, which influence the costs most, are taken totally or 
at least in part from different studies.19 20 22This harbours 
the risk of resulting in a very heterogeneous study popu-
lation with uncontrolled confounders. This risk can be 
minimised by deriving data from RCTs with well- balanced 
patient cohorts as recently published.17 23
For our analysis, we used a different approach than a 
decision tree: factual variables and outcome data derived 
from the only prospective study on EFTR treatment, and 
not from assumptions. The simulation of the control 
arm had to be performed due to the lack of RCTs in this 
setting. The strength of our study is that the very same 
clinician who actually performed the respective EFTR 
could review the different lesions and decide on a solid 
basis which treatment alternative he or she would have 
used instead of EFTR. In our view this approach reflects 
the clinical situation more precisely than a decision tree 
model.
In most CEAs, the costs per quality- adjusted life years 
are calculated and taken for healthcare decisions. 
Neither survival nor quality of life measurements were 
part of the WALL RESECT trial. In line with most of the 
recently published CEA, we calculated costs per defined 
outcome as the primary endpoint.17 19 20 22 23
Our study has several limitations. First, the compar-
ison arm of the study is based on simulation, so there is 
always a risk of a bias. Second, our analysis is specific to 
the German healthcare system and may therefore not be 
fully comparable with different healthcare systems in the 
world. Third, the estimated R0 rate for the SER methods 
is very low and likely due to the piecemeal resection in the 
respective study. If efficacy would have been measured 
as ‘freedom of recurrence’, efficacy would be higher (as 
proven in the Australian Colonic Endoscopic study).24 
Nonetheless, we used the published R0 rate because of 
the possibility to match this with the endpoint of the 
WALL RESECT study. Furthermore, as described above, 
an endpoint such as freedom of recurrence cannot be 
determined reliably as such data do not exist for EFTR. 
Fourth, costs of complications and follow- up were not 
included. This is mainly due to lack of an RCT and the 
short follow- up period. In an ideal CEA, all treatment- 
related and hospital stay- related costs would have been 
calculated.
In conclusion, our data indicate that EFTR for 
difficult- to- treat lesions of the colorectum is cost- effective 
compared with surgical and endoscopic treatment alter-
natives. The results are consistent both from a care 
provider as well as from a third- party payer perspective. 
RCTs and long- term follow- up are needed to further 
assess the cost- effectiveness of EFTR.
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